Vorozole

Chemical compound

L02BG05 (WHO)

Pharmacokinetic dataBioavailabilityVery highMetabolismHepaticElimination half-life8 hoursIdentifiers

IUPAC name

6-[(4-Chlorophenyl)(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole

CAS Number

129731-10-8^N

PubChem CID

6918191

ChemSpider

5293402^Y

UNII

1E2S9YXV2A

KEGG

D03786^Y

ChEMBL

ChEMBL224060^Y

CompTox Dashboard (EPA)

DTXSID20156230

Chemical and physical dataFormulaC₁₆H₁₃ClN₆Molar mass324.77 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

Clc1ccc(cc1)[C@@H](c2ccc3nnn(c3c2)C)n4ncnc4

^NY (what is this?) (verify)

Vorozole (developmental code name R-76713; former tentative brand name Rizivor) is a triazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.^[1]

References

^ Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Research and Treatment. 49. 49 (Suppl 1): S59-65, discussion S73-7. doi:10.1023/a:1006052923468. PMID 9797019. S2CID 28231447.